One-week glucose control via zero-order release kinetics from an injectable depot of glucagon-like peptide-1 fused to a thermosensitive biopolymer
Open Access
- 1 June 2017
- journal article
- research article
- Published by Springer Nature in Nature Biomedical Engineering
- Vol. 1 (6) , 1-14
Abstract
Stimulation of the glucagon-like peptide-1 (GLP1) receptor is a useful treatment strategy for type 2 diabetes due to pleiotropic effects, such as the regulation of islet hormones and the induction of satiety. However, the native ligand for the GLP1 receptor has a short half-life owing to enzymatic inactivation and rapid clearance. Here, we show that a subcutaneous depot formed after a single injection of GLP1 recombinantly fused to a thermosensitive elastin-like polypeptide results in zero-order release kinetics and circulation times of up to 10 days in mice and 17 days in monkeys. The optimized pharmacokinetics lead to 10 days of glycaemic control in three different mouse models of diabetes, as well as the reduction of glycosylated haemoglobin levels and weight gain in ob/ob mice treated once weekly for 8 weeks. Our results suggest that the optimized GLP1 formulation could enhance therapeutic outcomes by eliminating peak-and-valley pharmacokinetics and improving overall safety and tolerability. The design principles that we established should be broadly applicable for improving the pharmacological performance of other peptide and protein therapeutics.Keywords
This publication has 68 references indexed in Scilit:
- An Evidence-Based and Practical Approach to Using Bydureon in Patients With Type 2 DiabetesThe Journal of the American Board of Family Medicine, 2013
- GLP ‐1 receptor activated insulin secretion from pancreatic β‐cells: mechanism and glucose dependenceDiabetes, Obesity and Metabolism, 2012
- Applications of Human Pharmacokinetic Prediction in First-in-Human Dose EstimationThe AAPS Journal, 2012
- Encapsulation of Exenatide in Poly-( d,l -Lactide-Co-Glycolide) Microspheres Produced an Investigational Long-Acting Once-Weekly Formulation for Type 2 DiabetesDiabetes Technology & Therapeutics, 2011
- Effects of increasing doses of glucagon-like peptide-1 on insulin-releasing phases during intravenous glucose administration in miceAmerican Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 2011
- An overview of once‐weekly glucagon‐like peptide‐1 receptor agonists—available efficacy and safety data and perspectives for the futureDiabetes, Obesity and Metabolism, 2011
- Delivery of Therapeutic ProteinsJournal of Pharmaceutical Sciences, 2010
- Recursive Directional Ligation by Plasmid Reconstruction Allows Rapid and Seamless Cloning of Oligomeric GenesBiomacromolecules, 2010
- Immunogenicity of biologically-derived therapeutics: Assessment and interpretation of nonclinical safety studiesRegulatory Toxicology and Pharmacology, 2009
- Effects of Hofmeister Anions on the Phase Transition Temperature of Elastin-like PolypeptidesThe Journal of Physical Chemistry B, 2008